Ovarian Cancer

Revised federal guidelines recommend that more women, especially cancer survivors, be considered for genetic screening for hereditary breast and ovarian cancer.

I was never any good at math, but I can count. So I learned to live by this bit of information by counting the days that passed after my treatments for ovarian cancer.

The Food and Drug Administration’s recent approval of Zejula for certain patients with advanced ovarian, fallopian tube or primary peritoneal cancer was the first PARP inhibitor approved for the treatment, not the maintenance, of these women.

Looking back on Day One in the chemotherapy journey.

The Food and Drug Administration has approved Zejula for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer that have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency-positive status.

Before getting genetic testing for hereditary ovarian, breast or other cancers, make sure the company providing it is both reputable and qualified.

"They say once you hear the word cancer, you retain maybe 40 percent of the information that follows, but the words 'ovarian cancer' got through alright."

An ovarian cancer survivor shares what she wishes she had known then with those who are newly diagnosed.

Knowing your family history is the first preventative step any woman can take to avoid a diagnosis of ovarian cancer.

"I don’t have cancer, but here I am. This is my life. This is my reality. I am BRCA positive."

CURE spoke with an expert on how patients can better advocate for themselves when it comes to genetic testing and its follow-up.

Ovarian Cancer Research Alliance (OCRA) supports women and their families going through an ovarian cancer diagnosis, while also funding the research that will one day lead to its prevention.

Frontline maintenance therapy with Zejula lengthened time without disease progression among women with newly diagnosed, advanced ovarian cancer, according to findings from the phase 3 PRIMA study.

The addition of Lynparza to maintenance therapy with Avastin improved time to disease progression in women with advanced ovarian cancer, according results of the PAOLA-1/ENGOT-ov25 trial.

CURE spoke with an expert from Mount Sinai to discuss the future of ovarian cancer treatment and his advice for women facing a new diagnosis.

“For so long ovarian cancer has been a secret part of my life. That’s over now.”

"I’m a work in progress. I work to heed my oncologist’s advice: Don’t spoil today by worrying about tomorrow."

A rare type of ovarian tumor can raise testosterone levels, causing women to develop male characteristics. The main treatments: surgery and chemotherapy.

September is Ovarian Cancer Awareness Month. Here’s a round-up of the latest news and updates in this disease space.

From a return to work for Alex Trebek to a personalized Backstreet Boys concert, here’s what is making headlines in the cancer space this week.

The US Preventive Services Task Force now recommends for genetic counseling and testing for survivors of certain cancer types, but many at high-risk for the disease are left off the list.

In a new study, Zejula (niraparib) has been shown to prolong life for patients with ovarian cancer who have already undergone four or more rounds of chemotherapy.